EvaluatePharma

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor sit amet

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aenean commodo ligula eget dolor.
  • Aenean massa consequat massa quis enim. nenatis vitae, justo

Lorem ipsum dolor sit amet

2019Deals.png

Deals


We offer comprehensive coverage of M&A, licensing, venture financing and IPO deals in the pharmaceutical and biotech space. You can track and benchmark deals by product classification (phase of development, therapy area, technology and phase of compounds) and review deal values, upfront payments, royalties and co-promotions.

You can also evaluate any company’s M&A record, tracking the progress of their products after acquisition.

Portfolio and pipeline analysis


EvaluatePharma covers R&D pipeline information at each stage of the process, from research and development to filed and approved. You can cut the data with multiple lenses including phase, indication, therapy area, mechanism of action, company and technology – building a customised view of the development landscape.

You can also see the history of regulatory approvals, including FDA (USA), EMA (EU), PMDA (Japan) and ANVISA (Brazil), and key patent expiration dates.


Company financials


Our extensive company-level financial information – both historical and forecast – lets you understand the leading companies in the industry in terms of their revenues and profits. Financials include profit and loss (reported and normalised), balance sheet and cash flow information, as well as valuation measures.

Our historical and forecast company models also cover product sales, therapy area sales, pharmaceutical and non-pharmaceutical segments and portfolio performance, all the way through to 2026.

Consensus forecasts to 2026


Our deep industry knowledge and analytical expertise allow us to create the highest quality consensus forecasts and give our clients solid benchmarks for their strategic decisions.

Now extended to 2026, you get greater visibility into the future of the pharma industry, so you can plan ahead with confidence.

Our industry leading broker coverage lets us go deeper than our competitors. With both historical and forecast sales broken down by indication, you can understand the indication-specific dynamics of each market.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Archived forecasts

We have the largest back catalogue of consensus drug forecasts: 485,000 forecasts covering 11,000+ drugs since January 2003, including a monthly archive of Evaluate’s consensus forecasts so you can see changes versus the current forecast.

We provide unique insight into equity analysts’ changing sales expectations through a drug’s life cycle, so you can monitor a drug’s progression and understand changes in its forecast commercial potential.

EventAnalyzer

Our EventAnalyzer reveals the news events that affect pharmaceutical and biotech company share prices and valuations.

We calculate the share price and market capitalisation change for each event, and keep you up to date with daily and weekly round-ups of stock price winners and losers.


Lorem ipsum

Download our white papers

Three resources for the professionally curious

Schedule EvaluatePharma Vision demo >
Stimulus      
Daily news with expert analysis
Interviews with industry leaders
Company & product events coverage
Response      
Consensus forecasts to 2024  
Archived consensus forecasts  
Sales by indication  
Therapy area, mechanism of action, and other classifications  
Licensing deals, M&A, venture financing and IPOs  
Orphan drugs and biosimilars analysis  
Success rate benchmarks (PTRS)    
Time-in-phase benchmarks by indication    
Comprehensive product and trial level R&D costs    
Clinical trials design and outcomes    
Net Present Value calculator    
Calendar of market events and catalysts    

TESTIMONIAL